UK health committee to investigate pharma regulation after Brexit

The UK’s House of Commons has launched an investigation into post-Brexit regulatory agreements needed to guarantee the safe and effective supply of medicines and medical devices.

Parliament’s health committee announced the enquiry on Thursday, September 21.

When the UK withdraws from the EU, new regulatory arrangements must already be in place to ensure the supply of medicines, medical devices, medical products and substances of human origin.

“Patients, the National Health Service and the UK’s life sciences industry need certainty about what the UK’s regulatory arrangements will be after Brexit and a smooth transition towards them,” said the committee.

The committee has requested submissions, to be received by October 26, on a number of issues.

Respondents were asked to list the key considerations that arise for companies, healthcare services and regulatory bodies in the UK as a result of Brexit, and what can be done to ensure any adverse impact is minimised.

The committee has also asked for submissions on what alternative arrangements for the regulation could be introduced and how much time is needed to facilitate a smooth transition to these arrangements.

“How will withdrawal from the EU affect the UK’s ability to influence international standards in life sciences?” asked the committee.

Another question the committee raised was the implications of Brexit on research and development in the UK.

In August, LSIPR reported that the UK government had committed £160 million ($280.2 million) in funding to the life sciences after a review of the industry.

Did you enjoy reading this story?  Sign up to our free newsletters and get stories like this sent straight to your inbox.